Signet Ring Cell Carcinoma Treatment Chemotherapy

A team from the first hospital of jilin university in china wanted to know if chemotherapy was necessary after tumor removal surgery.

Signet ring cell carcinoma treatment chemotherapy. Signet ring cell carcinoma treatment. One rare type of colorectal cancer signet ring cell carcinoma was the subject of a new study evaluating whether or not adjuvant therapy after surgery was effective. Signet ring cell carcinoma srcc is a rare form of highly malignant adenocarcinoma that produces mucin it is an epithelial malignancy characterized by the histologic appearance of signet ring cells. Signet ring cell carcinoma srcc has been associated with poor prognosis and is defined as one of the most malignant cancers compared with other colorectal cancers.

Typically this cancer is presented with scattered infiltration of the gastric wall. The occurrence of signet ring cell cancer in some cases is associated with hereditary factors usually linked to the mutations in the cdh1 gene which encodes the vital. Signet ring cell cancer accounts for nearly 8 7 percent of the cases of all gastric cancers. These cancerous cells are very aggressive in growth as compare to non signet cells and the addition of late detection makes it only worse.

Signet ring cell carcinoma is less chemosensitive than others and the increase in the percentage of signet ring cells correlates with resistance to chemotherapy. Perioperative chemotherapy in advanced signet ring cell carcinomas is an independent factor of poor prognosis and survival which is explained by the toxicity of neoadjuvant treatment.